Company / Assets per Share
Taysha Gene Therapies, Inc. Assets per Share History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Assets per Share
$1.68
FY2025
5-year range
$0.86 / $5.68
FY2021-FY2025
Trend
+95.3%
vs FY2024
Sector context
#194 of 210
Health Care
What the data says
Among 210 Health Care companies, Taysha Gene Therapies, Inc. is in the bottom 8% for assets per share. Assets per Share returned to growth in FY2025 after 4 years of decline, reaching $1.68.
Based on SEC 10-K filings.
1.68 in FY2025 with a 5-year CAGR of -35.2%.
Declined from $2.73 to $1.68 over the past 2 years.
Health Care sector context is included.
Assets per Share over time
Growth rates
- 3-Year CAGR
- -20.1%
- 5-Year CAGR
- -35.2%
- 10-Year CAGR
- -
Sector benchmark
Bottom 8% in Health CareTop 92% of 210This company $1.68 Sector average $353.15
▼
-99.5% below sector average
Key checks
Key Insights
- In FY2025, assets per share increased 95.3% year-over-year.
- Ranks #194 out of 210 companies in the Health Care sector.
- Peak assets per share was recorded in FY2020.
- Lowest assets per share in the period was in FY2024.
Company context
Key Data Points
- Altman Z-Score -1.03 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Assets per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.68 | +95.3% |
| FY2024 | $0.86 | -68.6% |
| FY2023 | $2.73 | -16.7% |
| FY2022 | $3.28 | -42.2% |
| FY2021 | $5.68 | -61.2% |
| FY2020 | $14.65 | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026